

Is increased epicardial fat thickness a marker of the presence of severe coronary artery disease?

Epikardiyal yağ kalınlığının artışı şiddetli koroner arter hastalığı varlığının bir belirtisi midir?

Fat is mainly deposited in subcutaneous tissue, but it also accumulates in the abdominal or thoracic region (1). Other major sites of fat accumulation are visceral and cardiac areas; Cardiac fat deposition is now recognized as a new cardiometabolic risk marker, as it is associated with increased insulin resistance, cardiovascular risk factors, as their measurement is practical (2). Fat accumulation in the heart appears in three different types: intracellular, epicardial and pericardial. Intracellular fat is the microscopic lipid accumulation within the cytoplasm of cardiac muscle and can be the result of myocardial ischemia, cell damage or cell death. Epicardial fat is located between the outer wall of the myocardium and the visceral layer of pericardium (3). Pericardial fat exists anterior to the epicardial fat layer and therefore located between visceral and parietal pericardium. Due to the close anatomic relation between myocardium and the epicardial fat, the two tissues share the same microcirculation (4). In previous studies have been reported that epicardial fat is metabolically active and is the source for several adipokines. Potential interactions through paracrine or vasocrine mechanisms between epicardial fat and myocardium are strongly suggested (4).

The study by Shemirani et al. (5) in this issue of The Anatolian Journal of Cardiology highlights the correlation between the echocardiographic epicardial fat thickness (EFT) and the severity of coronary artery disease (CAD). Echocardiographic EFT measurement was performed in a total of 292 subjects who were referred for coronary angiography. All subjects underwent coronary angiography and then they were classified into the 2 groups: normal and CAD. EFT was significantly increased in CAD group (5.4 ± 1.9 mm vs. 4.4 ± 1.8 mm, $p=0.0001$). EFT was also significantly correlated with the severity of CAD (Califf scoring) when the (partial correlation) confounding variables were controlled (Spearman $r=0.213$, $p=0.002$). EFT showed significant positive correlation with low-density lipoprotein, body mass index, serum triglyceride levels and waist circumference. The authors propose that transthoracic echocardiographically measured EFT is significantly correlated with the severe multiple

coronary artery stenosis in patients with known CAD and EFT could be used for in the risk stratification of those patients.

The finding regarding the significant correlation between the CAD severity and EFT in a relatively large population ($n=292$) who underwent invasive angiography is important. In agreement with this study, previous studies also reported a close relationship between the EFT and severity of CAD (6). However, these studies did not include a normal coronary artery group, which was documented by invasive angiography. Present study provides an additional information which allows to compare the EFT measurement between angiographically documented CAD group ($n=171$) and the subjects who had normal coronary angiography group ($n=121$).

Epicardial fat is thought to promote the development and progression of coronary atherosclerosis. Elevated inflammatory infiltrate has been described in epicardial fat of subjects with CAD (7). The paracrine or vasocrine secretion of epicardial inflammatory molecules, contributes to the metabolic and inflammatory milieu that also promotes atherogenesis (7). In vitro studies have shown that paracrine dialogs between human adipocytes and inflammatory cells present in adipose tissue (i.e., macrophage, lymphocytes, and others) promote an increased synthesis of numerous biomolecules, leading to a low-grade inflammatory microenvironment (8). These conditions most likely promote plaque formation and coronary stenosis. In accordance of these pathogenetic mechanisms, present study confirms the strong relationship between the epicardial adipose tissue deposition and the severity of coronary artery disease. But, large scale studies evaluating the relationship between EFT, inflammation and coronary atherosclerosis in patients with angiographically documented CAD may provide a more definite conclusion in this issue.

Califf scoring system, which was used for defining CAD severity by the authors of the present study. Authors cited an article related Califf scoring system, but in this article, Califf et al. (9) validated Duke Jeopardy Score which was developed by Dash et al. (10). Therefore, referring the Duke Jeopardy Score would be more accurate.

Address for Correspondence/Yazışma Adresi: Dursun Duman MD, İstanbul Medipol Üniversitesi, Tıp Fakültesi, Unkapanı Yerleşkesi, Atatürk Bulvarı No:27, 34083 Fatih, İstanbul-Türkiye Phone: +90 212 444 85 44 Fax: +90 212 453 48 00 E-mail: dduman@medipol.edu.tr

Accepted Date/Kabul Tarihi: 10.02.2012 **Available Online Date/Çevrimiçi Yayın Tarihi:** 24.02.2012

©Telif Hakkı 2011 AVES Yayıncılık Ltd. Şti. - Makale metnine www.anakarder.com web sayfasından ulaşılabilir.

©Copyright 2011 by AVES Yayıncılık Ltd. - Available on-line at www.anakarder.com

doi:10.5152/akd.2012.062

Epicardial fat can be measured with several imaging techniques. Multi-detector computed tomography (MDCT) or cardiac magnetic resonance imaging (MRI) clearly allows a precise, but more expensive and cumbersome measurement (11). However, echocardiographic assessment of EFT would certainly be less expensive than MDCT and MRI. Additionally, echocardiography is simple, accurate and routinely performed in high-risk cardiac patients. In addition to previous studies, present study supports that echocardiographic epicardial fat measurement may play a role in the prediction of severity of coronary involvement in patients with CAD.

Dursun Duman

Department of Cardiology, Faculty of Medicine, İstanbul Medipol University, İstanbul-Turkey

Conflict of interest: None declared.

References

1. Van Herpen NA, Schrauwen-Hinderling VB. Lipid accumulation in non-adipose tissue and lipotoxicity. *Physiol Behav* 2008; 94: 231-41. [\[CrossRef\]](#)
2. Nicklas BJ, Penninx BW, Cesari M, Kritchevsky SB, Newman AB, Kanaya AM, et al. Association of visceral adipose tissue with incident myocardial infarction in older men and women: the Health, Aging and Body Composition Study. *Am J Epidemiol* 2004; 160: 741-9. [\[CrossRef\]](#)
3. Rabkin SW. Epicardial fat: properties, function and relationship to obesity. *Obes Rev* 2007; 8: 253-61. [\[CrossRef\]](#)
4. Iacobellis G, Ribaldo MC, Zappaterreno A, Iannucci CV, Leonetti F. Relation between epicardial adipose tissue and left ventricular mass. *Am J Cardiol* 2004; 94: 1084-7. [\[CrossRef\]](#)
5. Shemirani H, Khoshavi M. Correlation of echocardiographic epicardial fat thickness with severity of coronary artery disease-an observational study. *Anadolu Kardiyol Derg* 2012;12: 00.00.
6. Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, et al. Echocardiographic epicardial fat thickness and coronary artery disease. *Circ J* 2007; 71: 536-9. [\[CrossRef\]](#)
7. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. *Circulation* 2003; 108: 2460-6. [\[CrossRef\]](#)
8. Keophiphath M, Achard V, Henegar C, Rouault C, Clement K, Lacasa D. Macrophage-secreted factors promote a profibrotic phenotype in human preadipocytes. *Mol Endocrinol* 2009; 23: 11-24. [\[CrossRef\]](#)
9. Califf RM, Phillips HR 3rd, Hindman MC, Mark DB, Lee KL, Behar VS, et al. Prognostic value of a coronary artery jeopardy score. *J Am Coll Cardiol* 1985; 5: 1055-63. [\[CrossRef\]](#)
10. Dash H, Johnson RA, Dinsmore RE, Harthorne JW. Cardiomyopathic syndrome due to coronary artery disease. I: Relation to angiographic extent of coronary disease and to remote myocardial infarction. *Br Heart J* 1977; 39: 733-9. [\[CrossRef\]](#)
11. Sarin S, Wenger C, Marwaha A, Qureshi A, Go BD, Woomert CA, et al. Clinical significance of epicardial fat measured using cardiac multislice computed tomography. *Am J Cardiol* 2008; 102: 767-71. [\[CrossRef\]](#)